Matches in Nanopublications for { ?s ?p "[Dasatinib, a novel, oral, multitargeted kinase inhibitor of BCR-ABL and SRC family kinases, has previously induced responses in patients with imatinib-resistant or -intolerant Ph-positive ALL.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- NP791998.RADbhT3JCbFITf2AIxLLkPADbmJa6Tnyam-NG37chhZ1k130_assertion description "[Dasatinib, a novel, oral, multitargeted kinase inhibitor of BCR-ABL and SRC family kinases, has previously induced responses in patients with imatinib-resistant or -intolerant Ph-positive ALL.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP791998.RADbhT3JCbFITf2AIxLLkPADbmJa6Tnyam-NG37chhZ1k130_provenance.
- assertion description "[Dasatinib, a novel, oral, multitargeted kinase inhibitor of BCR-ABL and SRC family kinases, has previously induced responses in patients with imatinib-resistant or -intolerant Ph-positive ALL.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP609456.RAf99SbHNqxWbmWJbGmhLA3FE3MrdHp6agw8cKraYPtaY130_assertion description "[Dasatinib, a novel, oral, multitargeted kinase inhibitor of BCR-ABL and SRC family kinases, has previously induced responses in patients with imatinib-resistant or -intolerant Ph-positive ALL.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP609456.RAf99SbHNqxWbmWJbGmhLA3FE3MrdHp6agw8cKraYPtaY130_provenance.
- NP609457.RAQbO6wORL9rP5joUPZA2zb6LucyJFt5xNaEMAO2nAJ8Q130_assertion description "[Dasatinib, a novel, oral, multitargeted kinase inhibitor of BCR-ABL and SRC family kinases, has previously induced responses in patients with imatinib-resistant or -intolerant Ph-positive ALL.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP609457.RAQbO6wORL9rP5joUPZA2zb6LucyJFt5xNaEMAO2nAJ8Q130_provenance.
- NP712132.RANIggHw9Mlx5T64OgPbDlhncmBdH7LLjN-ZybCl1Psbk130_assertion description "[Dasatinib, a novel, oral, multitargeted kinase inhibitor of BCR-ABL and SRC family kinases, has previously induced responses in patients with imatinib-resistant or -intolerant Ph-positive ALL.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP712132.RANIggHw9Mlx5T64OgPbDlhncmBdH7LLjN-ZybCl1Psbk130_provenance.